Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone

Cited by (578)

Items 101–200 of 578

1. Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use
   Shannon Gwin Mitchell, Jan Gryczynski, Robert P. Schwartz, C. Patrick Myers, Kevin E. O’Grady, Yngvild K. Olsen, Jerome H. Jaffe · 2015 · Journal of Psychoactive Drugs
2. The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis
   Hannah K. Knudsen · 2015 · Journal of Studies on Alcohol and Drugs
3. The Useage of Opioids and their Adverse Effects in Gastrointestinal Practice: A Review.
   MahmoudReza Khansari, MasourReza Sohrabi, Farhad Zamani · 2013 · Europe PMC (PubMed Central)
4. Patients' Reasons for Choosing Office-Based Buprenorphine: Preference for Patient-Centered Care
   Philip Todd Korthuis, Jessica L. Gregg, Wendy E. Rogers, Dennis W. McCarty, Christina Nicolaidis, Joshua F. Boverman · 2010 · Journal of Addiction Medicine
5. Practical Consideration for the Clinical Use of Buprenorphine
   Hendrée E. Jones · 2004 · Science & Practice Perspectives
6. Buprenorphine Treatment for Adolescents and Young Adults With Opioid Use Disorders: A Narrative Review
   Jacob T. Borodovsky, Sharon Levy, Marc J. Fishman, Lisa A. Marsch · 2018 · Journal of Addiction Medicine
7. Buprenorphine and its formulations: a comprehensive review
   Salomon Poliwoda, Nazir Noor, Jack S. Jenkins, Cain W. Stark, Mattie Steib, Jamal J. Hasoon, Giustino Varrassi, Ivan Urits, Omar Viswanath, Adam Marc Kaye et al. · 2022 · Health Psychology Research
8. Use of Buprenorphine for Addiction Treatment: Perspectives of Addiction Specialists and General Psychiatrists
   Cindy Lou Parks, Sharon Reif, S. Haq, Stanley S. Wallack, Alex Hoyt, Grant A. Ritter · 2008 · Psychiatric Services
9. Treating Perioperative and Acute Pain in Patients on Buprenorphine: Narrative Literature Review and Practice Recommendations
   Megan Buresh, Jessica Ratner, Aleksandra E Zgierska, Vitaly Gordin, Anika A. H. Alvanzo · 2020 · Journal of General Internal Medicine
10. A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
    Lynn E. Sullivan, Declan T. Barry, Brent A. Moore, Marek Cezary Chawarski, Jeanette M. Tetrault, Michael V. Pantalon, Patrick G. O’Connor, Richard S. Schottenfeld, David A. Fiellin · 2006 · Clinical Infectious Diseases
11. The Prescription Opioid Addiction Treatment Study: What have we learned
    Roger D. Weiss, Vinod Rao · 2017 · Drug and Alcohol Dependence
12. Opioid Antagonists, Partial Agonists, and Agonists/Antagonists: The Role of OfficeBased Detoxification
    Standiford Helm · 2008 · Pain Physician
13. Use and misuse of buprenorphine in the management of opioid addiction
    Theodore J. Cicero, Hilary L. Surratt, James A. Inciardi · 2007 · Journal of Opioid Management
14. The Association between Cocaine Use and Treatment Outcomes in Patients Receiving Office‐Based Buprenorphine/Naloxone for the Treatment of Opioid Dependence
    Lynn E. Sullivan, Brent A. Moore, Patrick G. O’Connor, Declan T. Barry, Marek Cezary Chawarski, Richard S. Schottenfeld, David A. Fiellin · 2009 · American Journal on Addictions
15. Predictive Factors for Relapse in Patients on Buprenorphine Maintenance
    Ferri, Michael, Finlayson, Alistair J. Reid, Wang, Li, Martin, Peter R. · 2014 · The American Journal on Addictions
16. Receipt of opioid agonist treatment in the Veterans Health Administration: Facility and patient factors
    Elizabeth M. Oliva, Alex H. S. Harris, Jodie A. Trafton, Adam J. Gordon · 2011 · Drug and Alcohol Dependence
17. Policies Related to Opioid Agonist Therapy for Opioid Use Disorders: The Evolution of State Policies from 2004 to 2013
    Rachel M. Burns, Rosalie Liccardo Pacula, Sebastian Bauhoff, Adam J. Gordon, Hollie Hendrikson, DOUGLAS L. LESLIE, Bradley D. Stein · 2015 · Substance Abuse
18. “They're making it so hard for people to get help:” Motivations for non-prescribed buprenorphine use in a time of treatment expansion
    Katherine J. McLean, Philip R. Kavanaugh · 2019 · International Journal of Drug Policy
19. A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes
    Ingunn Olea Lund, Gabriele Fischer, Gabrielle Katrine Welle-Strand, Kevin E. O’Grady, Kimber Debelak, William R. Morrone, Hendrée E. Jones · 2013 · Substance Abuse Research and Treatment
20. Buprenorphine in the Treatment of Opiate Dependence
    Donald R. Wesson, David Eugene Smith · 2010 · Journal of Psychoactive Drugs
21. Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification.
    Standiford Helm, Andrea M. Trescot, James D. Colson, Nalini Sehgal, Sanford M. Silverman · 2008 · PubMed
22. Craving predicts opioid use in opioid-dependent patients initiating buprenorphine treatment: A longitudinal study
    Judith I. Tsui, Bradley J. Anderson, David R. Strong, Michael D. Stein · 2014 · The American Journal of Drug and Alcohol Abuse
23. The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol
    Brittany Burns Dennis, Leen Naji, Monica Bawor, Ashley Bonner, Michael Varenbut, Jeff Daiter, Carolyn Plater, Guillaume Paré, David C. Marsh, Andrew Worster et al. · 2014 · Systematic Reviews
24. Buprenorphine-naloxone Treatment for Pre-release Opioid-dependent Inmates in Puerto Rico
    Carmen Albizu Garcia, Glorimar Caraballo Correa, Adriana D. Hernandez Viver, T. Kinlock, M. Gordon, C. A. Avila, Ivette Reyes, R. Schwartz · 2007 · Journal of addiction medicine
25. Buprenorphine treatment in an urban community health center: what to expect.
    Chinazo O. Cunningham, Angela Giovanniello, Galit M. Sacajiu, Susan D. Whitley, Pamela A. Mund, Robert Beil, Nancy Sohler · 2008 · PubMed
26. Attending physicians' and residents' attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital.
    Chinazo O. Cunningham, Nancy Sohler, Kate McCoy, Hillary V. Kunins · 2006 · PubMed
27. Identifying and ranking implicit leadership strategies to promote evidence-based practice implementation in addiction health services
    Erick G. Guerrero, Howard Padwa, Karissa M. Fenwick, Lesley Maradik Harris, Gregory A. Aarons · 2015 · Implementation Science
28. Public Health Behind Bars
    Heath, Mark · 2007 · Springer eBooks
29. Managing opioid addiction with buprenorphine.
    Paul A Donaher, Christopher Welsh · 2006 · PubMed
30. Buprenorphine therapy for opioid addiction in rural Washington: The experience of the early adopters
    Tyler L. Quest, Joseph O. Merrill, John M. Roll, Andrew J. Saxon, Roger A. Rosenblatt · 2012 · Journal of Opioid Management
31. Unobserved “Home” Induction Onto Buprenorphine
    Joshua D. Lee, Frank J. Vocci, David A. Fiellin · 2014 · Journal of Addiction Medicine
32. Craving and opioid use disorder: A scoping review
    Bethea A. Kleykamp, Marta De Santis, Robert H. Dworkin, Andrew S. Huhn, Kyle Matthew Kampman, Iván D. Montoya, Kenzie L. Preston, Tanya S. Ramey, Shannon M. Smith, Dennis C. Turk et al. · 2019 · Drug and Alcohol Dependence
33. Methods of Detoxification and Their Role in Treating Patients With Opioid Dependence
    Patrick G. O’Connor · 2005 · JAMA
34. History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder
    Christian A. Heidbreder, Paul J. Fudala, Mark K. Greenwald · 2023 · Drug and Alcohol Dependence Reports
35. Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: A discrete survival and growth mixture model
    Thomas F. Northrup, Angela L. Stotts, Charles Green, Jennifer Sharpe Potter, Elise N. Marino, Robrina Walker, Roger D. Weiss, Madhukar H. Trivedi · 2014 · Addictive Behaviors
36. A review of a national training initiative to increase provider use of MAT to address the opioid epidemic
    FRANCES RUDNICK LEVIN, Adam M. Bisaga, Maria A. Sullivan, Arthur Robin Williams, Kathryn Cates‐Wessel · 2016 · American Journal on Addictions
37. Models for Integrating Buprenorphine Therapy into the Primary HIV Care Setting
    Sanjay Basu, Duncan Smith-Rohrberg, Robert Douglas Bruce, Fredrick L. Altice · 2006 · Clinical Infectious Diseases
38. Narrative Review: Buprenorphine for Opioid-Dependent Patients in Office Practice
    Lynn E. Sullivan, David A. Fiellin · 2008 · Annals of Internal Medicine
39. Buprenorphine for the treatment of opioid dependence
    Lisa A Boothby, Paul L. Doering · 2007 · American Journal of Health-System Pharmacy
40. Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials
    Jihoon Lim, Imen Farhat, Antonios Douros, Dimitra Panagiotoglou · 2022 · PLoS ONE
41. Choosing a behavioral therapy platform for pharmacotherapy of substance users
    Kathleen M. Carroll, Thomas R. Kosten, Bruce J. Rounsaville · 2004 · Drug and Alcohol Dependence
42. Network therapy: Decreased secondary opioid use during buprenorphine maintenance
    Marc S. Galanter, Helen Dermatis, Linda Glickman, Robert A. Maslansky, M.Brealyn Sellers, Erna Neumann, Claudia Rahman-Dujarric · 2004 · Journal of Substance Abuse Treatment
43. Buprenorphine: Its Role in Preventing HIV Transmission and Improving the Care of HIV-Infected Patients with Opioid Dependence
    L. E. Sullivan, David A. Fiellin · 2005 · Clinical Infectious Diseases
44. Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland
    Becky L. Genberg, Mirinda A. Gillespie, Charles Roberts Schuster, Chris‐Ellyn Johanson, Jacquie A. Astemborski, Gregory Dale Kirk, David Vlahov, Shruti H. Mehta · 2013 · Addictive Behaviors
45. Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine
    Philip Todd Korthuis, David A. Fiellin, Rongwei F. Fu, Paula J. Lum, Frederick Lewis Altice, Nancy Sohler, Mary Jo Tozzi, Steven M. Asch, Michael Botsko, Margaret Fishl et al. · 2011 · JAIDS Journal of Acquired Immune Deficiency Syndromes
46. Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio
    Todd D. Molfenter, Carol Sherbeck, Mark E. Zehner, Andrew Quanbeck, Dennis W. McCarty, Jee-Seon Kim, Sandy Starr · 2015 · Substance Abuse Treatment Prevention and Policy
47. A comparison of buprenorphine induction strategies: Patient-centered home-based inductions versus standard-of-care office-based inductions
    Chinazo O. Cunningham, Angela Giovanniello, Xuan Li, Hillary V. Kunins, Robert J. Roose, Nancy Sohler · 2011 · Journal of Substance Abuse Treatment
48. Opioid agonist treatment for people who are dependent on pharmaceutical opioids
    Suzanne Nielsen, Wai Chung Tse, Briony Larance · 2022 · Cochrane Database of Systematic Reviews
49. Partnerships and pathways of dissemination: The National Institute on Drug Abuse—Substance Abuse and Mental Health Services Administration Blending Initiative in the Clinical Trials Network
    Steve Martino, Gregory S. Brigham, Christine Higgins, Steve Gallon, Thomas E. Freese, Lonnetta M. Albright, Eric G. Hulsey, Laurie Krom, Susan A. Storti, Harold I. Perl et al. · 2010 · Journal of Substance Abuse Treatment
50. Impact of Chronic Pain on Treatment Prognosis for Patients with Opioid Use Disorder: A Systematic Review and Meta-analysis
    Brittany Burns Dennis, Monica Bawor, Leen Naji, Carol K. Chan, Jaymie Varenbut, James Paul, Michael Varenbut, Jeff Daiter, Carolyn Plater, Guillaume Paré et al. · 2015 · Substance Abuse Research and Treatment
51. The clinical efficacy and abuse potential of combination buprenorphine–naloxone in the treatment of opioid dependence
    Kristie Mammen, James R Bell · 2009 · Expert Opinion on Pharmacotherapy
52. Implementation of buprenorphine in the Veterans Health Administration: Results of the first 3 years
    Adam J. Gordon, Jodie A. Trafton, Andrew J. Saxon, Allen L. Gifford, Francine Goodman, Vincent S. Calabrese, Laura F. McNicholas, Joseph C. Liberto · 2007 · Drug and Alcohol Dependence
53. Research Network Involvement and Addiction Treatment Center Staff: Counselor Attitudes toward Buprenorphine
    Hannah K. Knudsen, Lori J. Ducharme, Paul Michael Roman · 2007 · American Journal on Addictions
54. Exploring first responders' perceptions of medication for addiction treatment: Does stigma influence attitudes?
    Nathan E. Kruis, Katherine J. McLean, Payton Perry · 2021 · Journal of Substance Abuse Treatment
55. Medications for opioid use disorder during incarceration and post-release outcomes
    Lara Cates, Aaron Brown · 2023 · Health & Justice
56. Office-Based Maintenance Treatment of Opioid Dependence
    Erik W. Gunderson, David A. Fiellin · 2008 · CNS Drugs
57. Evaluation of an improved sustained-release buprenorphine formulation for use in mice
    Jason Healy, Jennifer L. Tonkin, Stacey R. Kamarec, Mitchell A. Saludes, Sherif Y. Ibrahim, Rae R. Matsumoto, Jeffrey Wimsatt · 2014 · American Journal of Veterinary Research
58. Buprenorphine: new treatment of opioid addiction in primary care.
    Meldon Kahan, Anita Srivastava, Alice Ordean, Sharon Cirone · 2011 · PubMed Central
59. Abuse-Deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics
    Tammi H. Schaeffer · 2012 · Journal of Medical Toxicology
60. Office-Based Buprenorphine Treatment for Opioid-Dependent Patients
    Elinore F. McCance‐Katz · 2004 · Harvard Review of Psychiatry
61. A pilot study of buprenorphine—naloxone combination tablet (Suboxone®) in treatment of opioid dependence
    James R Bell, Gaye Byron, Amy Gibson, AMANDA MORRIS · 2004 · Drug and Alcohol Review
62. Update on the clinical use of buprenorphine: in opioid-related disorders.
    Simon Ducharme, Ronald Fraser, Kathryn Gill · 2012 · PubMed Central
63. Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study.
    Solomon Mamakwa, Meldon Kahan, Dinah Kanate, Mike Kirlew, David Folk, Sharon Cirone, Sara Rea, Pierre Parsons, Craig Edwards, Janet Gordon et al. · 2017 · Europe PMC (PubMed Central)
64. Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons
    Michael D. Stein, Debra S. Herman, Malyna Kettavong, Patricia A. Cioe, Peter D. Friedmann, Tahir Tellioğlu, Bradley J. Anderson · 2010 · Journal of Substance Abuse Treatment
65. MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study
    Schuman-Olivier, Zev, Borodovsky, Jacob T., Steinkamp, Jackson, Munir, Qays, Butler, Kyle, Greene, Mary Ann, Goldblatt, Jonah, Xie, Hai Yi, Marsch, Lisa A. · 2018 · Addiction Science & Clinical Practice
66. Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone
    Ernest V. Pedapati, Scot T. Bateman · 2010 · Pediatric Critical Care Medicine
67. The BHIVES Collaborative: Organization and Evaluation of a Multisite Demonstration of Integrated Buprenorphine/Naloxone and HIV Treatment
    Linda Weiss, James Erin Egan, Michael Botsko, Julie C. Netherland, David A. Fiellin, Ruth Finkelstein · 2011 · JAIDS Journal of Acquired Immune Deficiency Syndromes
68. Comparison of Buprenorphine Treatment for Opioid Dependence in 3 Settings
    Karen A. Miotto, Maureen P. Hillhouse, Roger A. Donovick, Jerry Cunningham‐Rathner, Charlie Charuvastra, Matthew Torrington, Asher E. Esagoff, Walter W Ling · 2011 · Journal of Addiction Medicine
69. Counselor Training and Attitudes toward Pharmacotherapies for Opioid Use Disorder
    Lydia Aletraris, Mary Bond Edmond, Maria Paino, Dail Fields, Paul Michael Roman · 2015 · Substance Abuse
70. Suboxone: Rationale, Science, Misconceptions.
    Jennifer R. Velander · 2018 · PubMed Central
71. Is residential treatment effective for opioid use disorders? A longitudinal comparison of treatment outcomes among opioid dependent, opioid misusing, and non-opioid using emerging adults with substance use disorder
    Zev Schuman‐Olivier, M. Claire Greene, Brandon G. Bergman, John Francis Kelly · 2014 · Drug and Alcohol Dependence
72. Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria
    Brittany Burns Dennis, Pavel S Roshanov, Leen Naji, Monica Bawor, James Paul, Carolyn Plater, Guillaume Paré, Andrew Worster, Michael Varenbut, Jeff Daiter et al. · 2015 · Trials
73. Factors Associated with Long-Term Retention in Buprenorphine-Based Addiction Treatment Programs: a Systematic Review
    Amy J. Kennedy, Charles B. Wessel, Rebecca E. Levine, Kendall Downer, Megan B. Raymond, Deborah Osakue, Iman F. Hassan, Jessica S. Merlin, Jane M. Liebschutz · 2021 · Journal of General Internal Medicine
74. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients
    Jeanette M. Tetrault, Brent A. Moore, Declan T. Barry, Patrick G. O’Connor, Richard S. Schottenfeld, David A. Fiellin, Lynn E. Fiellin · 2012 · Journal of Substance Abuse Treatment
75. Pharmacists’ and Technicians’ Perceptions and Attitudes Toward Dispensing Buprenorphine/Naloxone to Patients with Opioid Dependence
    Dennis W. Raisch, Paul J. Fudala, Andrew J. Saxon, Robert Walsh, Paul P. Casadonte, Walter W Ling, Bankole A. Johnson, Usha Malkerneker, Patricia Isbell Ordorica, William O. Williford et al. · 2005 · Journal of the American Pharmacists Association
76. Why Addiction Has a Chronic, Relapsing Course. The Neurobiology of Addiction
    Sharon A. Gutman · 2006 · Occupational Therapy in Mental Health
77. Heroin anticraving medications: a systematic review
    Fareed, Ayman, Vayalapalli, Sreedevi, Casarella, Jennifer, Amar, Richard, Drexler, Karen · 2010 · The American Journal of Drug and Alcohol Abuse
78. A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions
    Sara Ling, Remar A. Mangaoil, Kristin Cleverley, Beth Ann Sproule, Martine T.E. Puts · 2019 · Drug and Alcohol Dependence
79. Outcomes of Buprenorphine Maintenance in Office-Based Practice
    Stephen Magura, Stephen J. Lee, Edwin A. Salsitz, Andrew Kolodny, Susan D. Whitley, Tanaquil Taubes, Randy Seewald, Herman Joseph, Deborah J. Kayman, Chunki Fong et al. · 2007 · Journal of Addictive Diseases
80. Neurocognitive, psychiatric, and substance use characteristics in opioid dependent adults
    Franchesca Arias, Julia Hope Arnsten, Chinazo O. Cunningham, Kelly Coulehan, Abigail Batchelder, Mia Brisbane, Katie Segal, Mónica Rivera Mindt · 2016 · Addictive Behaviors
81. Opioid use and misuse: health impact, prevalence, correlates and interventions
    Maria Bolshakova, Ricky N. Bluthenthal, Steve Y. Sussman · 2019 · Psychology and Health
82. Two-year Experience with Buprenorphine-naloxone (Suboxone) for Maintenance Treatment of Opioid Dependence Within a Private Practice Setting
    James W. Finch, Jonathan B. Kamien, Leslie Amass · 2007 · Journal of Addiction Medicine
83. Probuphine® (buprenorphine implant): a promising candidate in opioid dependence
    Preeti Barnwal, Saibal Das, Somnath Mondal, Anand Ramasamy, Tanay Maiti, Arunava Saha · 2016 · Therapeutic Advances in Psychopharmacology
84. Opioid agonist therapy trajectories among street entrenched youth in the context of a public health crisis
    Valerie Giang, Madison Thulien, Ryan McNeil, Kali Sedgemore, Haleigh Anderson, Danya Fast · 2020 · SSM - Population Health
85. The effects of buprenorphine/naloxone maintenance treatment on sexual dysfunction, sleep and weight in opioid use disorder patients
    Sema Baykara, Kübra Alban · 2018 · Psychiatry Research
86. Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data
    Peter Hjelmström, Elin Banke Nordbeck, Fredrik Tiberg · 2020 · Drug Development and Industrial Pharmacy
87. Entry into primary care-based buprenorphine treatment is associated with identification and treatment of other chronic medical problems
    Rowe, Theresa A, Jacapraro, Janet S, Rastegar, Darius A · 2012 · Addiction Science & Clinical Practice
88. Buprenorphine physician supply: Relationship with state-level prescription opioid mortality
    Hannah K. Knudsen, Jennifer R. Havens, Michelle R. Lofwall, Jamie L. Studts, SHARON L. WALSH · 2017 · Drug and Alcohol Dependence
89. Primary care patient characteristics associated with completion of 6-month buprenorphine treatment
    Anne M. Neumann, Richard D. Blondell, Mohammadreza Azadfard, Ganon Nathan, Gregory G. Homish · 2013 · Addictive Behaviors
90. Buprenorphine/Naloxone for opioid dependence: clinical practice guideline.
    Curtis D. Handford, Meldon Kahan, Anita Srivastava, Sharon Cirone, Valerie A. Palda · 2011
91. Utilizing buprenorphine–naloxone to treat illicit and prescription-opioid dependence
    Ronald Fraser, Sofie Mauger, Kathryn Gill · 2014 · Neuropsychiatric Disease and Treatment
92. Dissatisfaction with opioid maintenance treatment partly explains reported side effects of medications
    Ashley Elizabeth Muller, Ronny Bjørnestad, Thomas Clausen · 2018 · Drug and Alcohol Dependence
93. A call for consensus in defining efficacy in clinical trials for opioid addiction: combined results from a systematic review and qualitative study in patients receiving pharmacological assisted therapy for opioid use disorder
    Brittany Burns Dennis, Nitika Sanger, Monica Bawor, Leen Naji, Carolyn Plater, Andrew Worster, Julia Woo, Anuja Bhalerao, Natasha Baptist-Mohseni, Alannah Hillmer et al. · 2020 · Trials
94. Health-related quality of life changes associated with buprenorphine treatment for opioid dependence
    Dennis W. Raisch, Heather M. Campbell, DA Garnand, Mark A. Jones, Mike R. Sather, Rupali K. Naik, Walter W Ling · 2011 · Quality of Life Research
95. Buprenorphine for opioid dependence
    Walter W Ling · 2009 · Expert Review of Neurotherapeutics
96. PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION
    Pr Depo-Provera · 2015
97. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees
    Hefei Wen, Jason M. Hockenberry, Harold A. Pollack · 2018 · JAMA Network Open
98. Age disparities in six-month treatment retention for opioid use disorder
    Carrie M. Mintz, Ned J. Presnall, John M. Sahrmann, Jacob T. Borodovsky, Paul E.A. Glaser, Laura Jean Bierut, Richard A. Grucza · 2020 · Drug and Alcohol Dependence
99. Rapid Quantification of Buprenorphine-Glucuronide and Norbuprenorphine-Glucuronide in Human Urine by LC-MS-MS
    Solfrid Hegstad, Hassan Z. Khiabani, Elisabeth Leere Øiestad, Thomas Berg, A S Christophersen · 2007 · Journal of Analytical Toxicology
100. Participant Characteristics and HIV Risk Behaviors Among Individuals Entering Integrated Buprenorphine/Naloxone and HIV Care
     Amina A. Chaudhry, Michael Botsko, Linda Weiss, James Erin Egan, Jennifer Adelson Mitty, Barbara D. Estrada, Gregory M. Lucas, Tanita Woodson, Timothy Flanigan, David A. Fiellin · 2011 · JAIDS Journal of Acquired Immune Deficiency Syndromes